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Abstract
Background: Due to their unique ability to bind their targets with high fidelity, antibodies are used widely not
only in biomedical research, but also in many clinical applications. Recombinant antibodies, including single chain
variable fragments (scFv), are gaining momentum because they allow powerful in vitro selection and manipulation
without loss of function. Regardless of the ultimate application or type of antibody used, precise understanding of
the interaction between the antibody’s binding site and its specific target epitope(s) is of great importance.
However, such data is frequently difficult to obtain.
Results: We describe an approach that allows detailed characterization of a given antibody’s target(s) using the
yeast two-hybrid system. Several recombinant scFv were used as bait and screened against highly complex cDNA
libraries. Systematic sequencing of all retained clones and statistical analysis allowed efficient ranking of the prey
fragments. Multiple alignment of the obtained cDNA fragments provided a selected interacting domain (SID),
efficiently narrowing the epitope-containing region.
Interactions between antibodies and their respective targets were characterized for several scFv. For AA2 and ROF7,
two conformation-specific sensors that exclusively bind the activated forms of the small GTPases Rab6 and Rab1
respectively, only fragments expressing the entire target protein’s core region were retained. This strongly sug-
gested interaction with a non-linear epitope. For two other scFv, TA10 and SF9, which recognize the large proteins
giantin and non-muscle myosin IIA, respectively, precise antibody-binding regions within the target were defined.
Finally, for some antibodies, secondary targets within and across species could be revealed.
Conclusions: Our method, utilizing the yeast two-hybrid technology and scFv as bait, is a simple yet powerful
approach for the detailed characterization of antibody targets. It allows precise domain mapping for linear
epitopes, confirmation of non-linear epitopes for conformational sensors, and detection of secondary binding
partners. This approach may thus prove to be an elegant and rapid method for the target characterization of
newly obtained scFv antibodies. It may be considered prior to any research application and particularly before any
use of such recombinant antibodies in clinical medicine.
Background
Because of their unique ability to recognize target anti-
gens with extremely high fidelity, antibodies remain an
essential tool in fundamental biomedical research and in
clinical diagnostic testing. In addition, they represent
one of the most promising novel therapeutic options, in
particular in the field of cancer treatment. Worldwide,
more than a thousand clinical trials have been com-
pleted and almost as many are currently underway using
monoclonal antibodies as pharmaceuticals http://www.
clinicaltrials.gov. Traditionally, monoclonal antibodies
have been produced from hybridoma cell lines in a
laborious process involving animal experimentation and
screening large numbers of clones. More recently,
recombinant monoclonal antibodies, which add an addi-
tional level of flexibility, have also become a viable treat-
ment option for various human diseases [1-9]. Several
alternatives to the classic in vivo selection of antibodies
have been developed and refined (for summary see
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[10]). One of the most prominent technique is antibody
phage display, which allows in vitro selection of single-
chain variable fragment (scFv) antibodies from complex
phage or phagemid libraries [11]. In this approach,
which has been utilized successfully in many labora-
tories, animal work is obviated entirely (for review see
[12,13]). It has been shown that scFv can even be manu-
factured for clinical use [14]. In our own research
laboratory, highly functional scFv antibodies that recog-
nize a broad range of targets, including evolutionarily
conserved proteins have been selected and characterized
[15-18].
Regardless of the type of production or ultimate appli-
cation, the effective use of antibodies depends on a
detailed understanding of the underlying antibody-anti-
gen interaction, i.e. knowledge about a given antibody’s
epitope(s). This holds true especially for clinical applica-
tions where such information would be of utmost
importance to accurately predict wanted and unwanted
(potentially harmful) biological effects. However, target
characterization of both traditional and recombinant
antibodies has been challenging. The gold standard of
such epitope mapping - analysis of the crystal structure
of a given antigen-antibody complex - is labor intensive
and sometimes nearly impossible due to technical diffi-
culties. Thus, often cumbersome strategies have to be
developed, like systematic target protein mutagenesis or
sub-fragment analysis. Examples of successful character-
ization of antibody targets through scanning mutagen-
esis and other techniques have been described elsewhere
[19,20]. More recently, combinatorial peptide phage dis-
play libraries have also been used [21,22]. In the future,
computer based or in silico combinatorial methods for
epitope mapping, like Mapitope [23] might prove useful.
Finally, epitope mapping has also become a powerful
strategy in the process of developing new vaccines
[24,25].
Here we describe an alternative approach to character-
ize the interaction between antibodies and their respec-
tive targets. Time- and resource-demanding
crystallography or mutagenesis experiments are circum-
vented. Instead the yeast two-hybrid (Y2H) technology
is employed. In most two-hybrid applications in the
recombinant antibody field, scFv are selected from a
prey library [26], Here, the system is inverted: previously
characterized scFv are used as bait and screened against
a comprehensive cDNA library. This new approach
yielded novel, detailed data about the targets of several
recombinant antibodies, including the need for tertiary
antigen structure for binding of conformational sensors,
mapping of precise epitopes and unveiling of secondary
targets.
Results and Discussion
Antibody targets are characterized using the two-hybrid
system with the scFv antibody as bait, a validated scoring
system to remove non-specific binders, and
determination of selected interacting domains
Investigators studying and selecting recombinant antibo-
dies have mostly used the Y2 H technology to select
antibody populations that fold correctly under the redu-
cing conditions of the cytosol [26-31]. In such experi-
ments, the epitope of a given antigen is defined and
used as a bait to sample a diverse scFv prey library.
Here, we reversed the system, using as baits known scFv
antibodies that had been previously selected in phage
display screens, and, as preys, proteins expressed from
high-complexity libraries of randomly primed cDNA
(Figure 1A).
Individual scFv antibodies were exposed to a cDNA
library with full coverage, derived from either human
placenta or from Drosophila. More than 50 million
potential interactions were tested during each screen.
Prey fragments of positive clones were identified using
sequence analysis and comparison with GenBank data-
bases using the BLAST algorithm [32]. Next, a Predicted
Biological Score (PBS) was computed for each clone as
described before [33], enabling classification according
to interaction reliability (Figure 1B). This permitted
ranking of the clones into categories from “A” to “D” in
decreasing probability of having a specific interaction
with the scFv-bait. Two additional categories were desig-
nated: “E”, interacting clones, which were likely retained
due to highly connected prey domains; and “F”, clones
that were experimentally proven Y2 H artifacts. In a
third step, overlapping prey fragments originating from
the same gene were designated as clusters and their
translated amino acid sequences were aligned and
superimposed onto the open reading frame (Figure 1C).
Overlapping regions shared by all fragments were desig-
nated as “selected interacting domain” (SID), as
described before [33].
For the conformation-specific antibodies AA2 and ROF7,
only large fragments are obtained, suggesting a non-
linear antibody binding-site
In the first screen, the scFv AA2 was used as bait. AA2
is a well-described conformation-specific antibody that
exclusively binds the activated (GTP bound) form of the
small GTPase Rab6 [17]. From the human cDNA prey
library only three specific binders were retained by Y2
H (Additional file 1). Two (67%) encoded for Rab6 (one
for Rab6a and one for Rab6b, Figure 2A, top). The
screen was repeated using a Drosophila cDNA library.
Eight specific clones were retained (Additional file 2),
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four (50%) representing Drosophila Rab6 (dRab6)
(Figure 2A, bottom).
The result of the Drosophila screen suggested that AA2,
which had been selected against human Rab6a, can also
recognize the fly Rab6a homologue. In our experience,
polyclonal anti-Rab6 antibodies (generated by immuniz-
ing rabbits with the full-length mammalian protein)
have failed to label dRab6 in immunofluorescence
(unpublished observations). In contrast, and in agree-
ment with the Y2 H data, AA2 labeling of dRab6 on
Golgi membranes was seen by immunofluorescence
(Figure 2B, a-c). Furthermore, analogous to what had
been shown in mammalian cells [17], AA2 was also
functional as an intrabody and labeled Golgi stacks in
living Drosophila S2 cells (Figure 2B, d-f). Our Y2 H
approach thus revealed that in addition to mammalian
Rab6, AA2 also detects the Drosophila homologue. This
is likely due to the fact that the three-dimensional struc-
ture of GTP-bound Rab6 remained highly conserved
throughout evolution.
In both Y2 H screens using AA2 as bait, only prey
fragments spanning most of the ORF were retained (Fig-
ure 2A, and Additional files 1 and 2). Apparently, the
entire core region of Rab6 had to be expressed to allow
binding of this conformation-sensitive antibody. This
further suggested that this method of target determina-
tion could validate non-linear epitopes. To confirm this,
we next characterized the target of another recently
obtained scFv, which was also observed to be conforma-
tion specific (own unpublished observations). This anti-
body, called ROF7, detects the small GTPase Rab1a
and/or Rab1b only after their activation through
GTP-loading. When the screen was performed using
ROF7 as bait, a total of 191 specifically interacting
clones were retained from the mammalian cDNA
library. Eighty percent (152 clones) encoded for Rab1a
or Rab1b, once again all encompassing the full core
region of the ORF (Figure 3 and Additional file 3).
In the two Y2 H screens using conformational sen-
sors as bait (AA2 and ROF7) and comprehensive prey
libraries, only targets expressing a sizable portion of
the protein (amino acids 2-178 for Rab1a, and 13-174
for Rab6a) were retained. Likely, fragments had to be
large enough to allow folding into proper tertiary
structure and GTP loading. The first few amino-term-
inal residues and the last 30 or so amino-acid long car-
boxy-terminal hypervariable tail are known to be
dispensable for correct three-dimensional assembly of
small GTPases. In fact, the crystal structure of Rab6b
was solved by expressing a recombinant protein that
contained only the core region of the protein (amino
acids 6-181) [34]. We believe that the residues, which
make up the epitopes for the binding of AA2 and
ROF7, respectively, are non-adjacent in the primary
amino acid sequence and only come together after cor-
rect folding of the polypeptide into tertiary structure
and subsequent activation through GTP binding. Lack
of reactivity of both antibodies on immunoblotting,
and results from the Y2 H screens strongly supports
this hypothesis.
In summary, our approach showed that for the con-
formation-specific sensors AA2 and ROF7 correct three-
dimensional antigen structures are needed to present
the antibody binding sites. It furthermore revealed that
Figure 1 Schematic depiction of the yeast-two-hybrid screen process using scFv as bait. A. The cDNA of selected scFv is fused to the
DNA binding domain of Gal4 (BD) and expressed in yeast as bait. A population of haploid yeast cells harboring short cDNA fragments fused to
the activation domain of Gal4 (AD) is then used for mating. Positive clones showing interaction between bait and prey are selected through the
expression of a reporter gene. (TM, Transcription Machinery). B. The Predicted Biological Score (PBS) is computed as described before [33] based
on a statistical model of the competition for bait binding between fragments. For practical purposes, numerical numbers are converted to
categories A through E as depicted. C. All fragments encoding for the same target ORF are aligned. This yields a selected interacting domain
(SID), which narrows the area containing the antibody’s binding epitope.
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Figure 2 Characterization of the scFv AA2 (anti-Rab6•GTP). A. Schematic alignment of human and drosophila Rab6 with translated
sequences of their respective cDNA of the interacting clones (numbers indicate amino acid position, vertical lines project the SID onto the full
length sequences). Note that in both cases the SID spans the entire core of the respective open reading frames (encoding for a protein of 208
amino acids each). B. AA2 recognizes the drosophila Rab6 homologue as antibody and as intrabody. AA2 as antibody: S2 insect cells were
fixed, stained with hAA2 (a, green in c) and co-stained with anti-Lava lamp (b, red in c). Panels a’, b’ and c’ represent a magnification of an area
within a, b and c. Rab6-containing Golgi membranes are decorated with hAA2 and surrounded by Lava-lamp-positive structures. AA2 as
intrabody: S2 cells were transfected with a plasmid expressing AA2 fused with GFP (d, green in f). Eighteen hours later cells were fixed and co-
stained with anti-Lava lamp antibodies (e, red in f). Panels d’, e’ and f’ represent a magnification of an area within d, e and f respectively. AA2 is
a functional intrabody in insect cells as it stains Golgi membranes like the AA2 antibody. Stronger labeling of Golgi structures with GFP was seen
in living cells (data not shown). Bar 10 μm.
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the AA2 epitope is conserved in evolution since dRab6
is recognized by the scFv.
For the anti-giantin antibody TA10, a small binding site
within the large coiled-coil protein giantin is determined
Next, we characterized the target of TA10. This scFv is
a recombinant antibody directed against a very large
(>350 kDa) Golgi-associated matrix protein called gian-
tin. TA10 was originally selected via phage display using
intact, purified, Golgi stacks as target [16].
The mammalian cDNA prey library was screened using
TA10 as bait. Sixty interacting clones were retained
(Additional file 4). Only one cluster, containing seven
clones, obtained a high PBS ranking; they all fell within
the central portion of the giantin ORF. Alignment of the
seven clones defined a ~28 kDa-large SID (Figure 4A)
located in the center portion of giantin. Binding of TA10
within this region of 250 amino acids was confirmed via
overexpression experiments (Figure 4B).
TA10 is a blotting antibody and thus, in contrast to
AA2 and ROF7, should detect the denatured protein at a
small linear binding site. Taking advantage of the flexibil-
ity of yeast genetics, we therefore attempted to narrow
the binding domain of TA10 further using a method
based on gap repair. Primers were designed along the
shortest of the seven prey fragments and PCR fragments
were generated (Figure 5A). The Y2 H screen was then
repeated, this time using the resulting small PCR pro-
ducts as prey (Figure 5B). In this manner, the TA10 bind-
ing region could be narrowed further to a single coiled
coil domain measuring 9kDa (fragment “a” in Figure 5C).
Binding of TA10 to this region was confirmed in overex-
pression experiments using both immunofluorescence
and Western blotting (Figure 5D, E). Finally, carrying out
additional biochemical and overexpression experiments
we narrowed the antibody-binding region even further
(within a 30 amino acid stretch, data not shown).
In summary, the Y2 H screen enabled rapid and accu-
rate target characterization for TA10. A precise region
of 79 amino acids, representing less than 2.5% of the
entire protein, was determined as its binding site.
For the non-muscle myosin IIA-targeting antibody SF9, a
precise epitope within a long coiled-coil protein is
determined and cross reactivity with human and other,
non-human, homologues is revealed
SF9 was selected alongside TA10 in a phage display
screen using purified rat liver Golgi stacks as the
Figure 3 Characterization of the scFv ROF7 (anti-Rab1•GTP). Schematic alignment of human Rab1a (A) and Rab1b (B) with the translated
sequences of cDNA fragments found in the ROF7 screen (numbers indicate amino acid position, vertical lines project the SID onto the full
length sequences). Note that in both cases the SID spans the entire core of the respective open reading frames (encoding for proteins of 205
and 201 amino acids, respectively).
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antigen. SF9’s target, non-muscle myosin IIA, was iden-
tified using immunoblotting followed by mass spectro-
metry analysis [16].
From the Y2 H screen with SF9 as bait a total of 352
specifically interacting clones were retained (Additional
file 5). More than half (196 clones) encoded for non-
muscle myosin IIA and their alignment allowed identifi-
cation of a very small SID of only 35 amino acids (Fig-
ure 6A). An additional 116 clones represented one of
two very closely related myosins: non-muscle myosin
IIB and smooth-muscle myosin (55 and 61 clones,
respectively). Their alignments yielded similarly precise
SID (Figure 6B, C). All three SID overlapped with one
another inside a conserved stretch of the tail region of
the myosin protein family, further narrowing the puta-
tive binding domain for SF9 (Figure 6D).
Binding of the antibody to the 29-amino-acid long
common SID was confirmed in a series of overexpres-
sion experiments. GFP-tagged non-muscle myosin IIA
constructs, which either included or lacked the SID
(Figure 7A), were overexpressed in mammalian cells. In
addition to the endogenous myosin pool, only the over-
expressed full-length but not the truncated protein was
recognized in immunofluorescence by SF9 (Figure 7B).
Immunoblot analysis revealed that a recombinant pro-
tein containing the 29-amino-acid long SID was
detected while no binding was seen with the construct
lacking this short region (Figure 7C). Together, this con-
firmed our Y2 H results.
Non-muscle myosins are evolutionarily conserved pro-
teins. In addition, SF9 was found to bind to a region of
the protein that shares near-identical amino acid
sequences between human homologues (Figure 6D).
Alignment of the SID with non-muscle myosins of other
species revealed a high degree of evolutionary conserva-
tion in this region even with the Drosophila counterpart
(Figure 7D). We thus speculated that SF9 might also
detect the insect form of myosin. Indeed, when using
total insect cell lysates a single ca. 200-kDa-large band
was detected by SF9. This signal completely disappeared
Figure 4 Characterization of scFv TA10 (anti-giantin). A. Schematic alignment of full-length rat giantin with the translated sequence of the
seven clones obtained from the TA10 screen (above) and the deletion construct used to confirm the localization of the interaction domain
(below). Numbers indicate amino acid position relative to the full-length rat giantin sequence; horizontal lines project the SID (~28 kDa) onto the
giantin sequence. This 250 amino-acid-long stretch is depicted in red. B. Confirmation of the ~28kDa large SID as the region which contains the
TA10 epitope. HeLa cells were transfected either with full-length rat giantin (a-c) or with a giantin construct lacking identified SID (d-f). Cells
were fixed 18 hours after transfection and double stained using a commercial anti-giantin antibody (green) and with hTA10 (red). Overexpression
of the full-length protein was detected by hTA10 (b and c), while the staining was unchanged or even diminished in cells transfected giantin
∆TABD (e and f). Arrows indicated cells that strongly overexpress the respective constructs. Bar 10 μm.
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after specific anti-myosin RNAi-mediated gene silencing
(Figure 7E).
In summary, our Y2H-approach allowed precise char-
acterization of the SF9 target, defining a very small
(<3kDa) epitope within a ~200kDa protein. In addition,
it revealed cross-reactivity with closely related proteins
of the same and across species.
Results of screens using antibodies that do not work as
intrabodies
Our novel approach yielded important additional infor-
mation about the targets of several distinct monoclonal
antibodies. However, some variability in the strength
and reliability of the data could be noted when compar-
ing individual screens. For instance, when screening
Figure 5 Determination and confirmation of a precise region within the SID as the TA10 binding domain. A. PCR fragments of different
size and location within the smallest prey clone from the initial screen were generated and labeled from 1 to 17. B. The two-hybrid yeast strain
containing the TA10 bait plasmid was transformed with the PCR products and a digested prey plasmid. The interactions of the prey fragment
were tested by spotting in media lacking histidine (left image). A b-galactosidase qualitative observation was also done to confirm the
interaction (right image). C. Alignment of the 17 PCR products with the human giantin amino acid sequence narrowed the putative TA10
binding domain to a 79-amino-acid long region (blue, labeled as “a”) between amino acids 1462 to 1540 of the full human sequence
(corresponding to amino acids 1399 to 1478 in the rat homologue). A fragment of 63 amino acids upstream of this region (labeled as “b”) was
used as negative control (see D and E). D. Confirmation using immunofluorescence. HeLa cells were transfected with a plasmid containing GFP
fused to either the fragment found using the gap repair approach (called giantin-TA10BDshort, a) or the negative control (called giantin-79aa
control, b). Only overexpression of the former was recognized by hTA10. E. Confirmation by Western blotting. The same two HeLa cell
populations described in D were harvested and prepared for Western blotting. Only giantin-TA10BDshort (a) but not giantin-79aa control (b) was
recognized by hTA10 while both were detected with anti-GFP.
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using yet another scFv, named F2C (an antibody which
binds a-tubulin [16]), results were less conclusive.
While a total of 380 interacting clones were obtained,
only 4 encoded for a-tubulin (data not shown). Their
alignment allowed narrowing of the epitope-containing
region to the C-terminal portion of the protein. How-
ever, many of the remaining 376 clones were also classi-
fied as possible binders using the PBS scoring method.
Nonetheless, it is unlikely that they represent secondary
targets for F2C given a highly specific signal of F2C in
both immunofluorescence and Western blotting [16].
Another scFv originating from the above mentioned
Golgi-stack screen, called TE5 [16], was tested in our
approach. While many interacting clones were retained,
none could be confirmed in overexpression experiments
and the TE5 target remained elusive so far (data not
shown). In sharp contrast to the just mentioned exam-
ples (F2C, TE5) our ROF7- and SF9-screens not only
confirmed the antibodies’ targets but also gave detailed
information about their respective epitopes: in each case
almost 90% of clones aligned within its target(s) (see
Figures 3 and 6). In agreement with the more classical
use of scFv in Y2 H [26] there seems to be a direct cor-
relation between the ability of an antibody to fold cor-
rectly under the reducing conditions of the eukaryotic
(yeast or mammalian) cytosol and their use in Y2 H.
While SF9, TA10, AA2 and ROF7 efficiently bind their
respective targets when expressed as intrabodies, F2C is
only faintly staining microtubules in living cells and TE5
never yielded specific staining as an intrabody. We thus
hypothesize that the same relative efficiency for target
recognition is present during the yeast two hybrid
experiments. To make full use of our method, it will
therefore be important to obtain good intrabodies, for
example via screening of dedicated libraries [35,36] or
through the use of single domain antibodies, like cameli-
dae antibodies, that seem to be more resistant to the
reducing conditions of the intracellular milieu [37].
Conclusions
We present a novel approach, which allows in-depth
characterization of antibody target(s) using the Y2 H
technology. In our approach the traditional orientation
of prey and bait is reversed, complex cDNA prey
libraries are screened, and a robust scoring system to
eliminate non-specific binders is employed. This way,
critical new information about antibodies’ targets can be
obtained. This includes strong corroborative evidence
for conformational specificity and the need for a non-
linear epitope for conformational antibodies, precise
mapping of small epitopes, and information about cross
reactivity within and across species.
In summary, our Y2 H approach represents a powerful
method for the detailed characterization of scFv/anti-
body targets. Given the high quantity and quality of new
data that can be obtained from a simple experiment, we
believe that our approach might in the future serve as
an invaluable tool for the detailed target characterization
of many types of antibodies.
Methods
Preparation of bait vectors, Y2 H cloning strategy, Y2 H
screens
The plasmids pHEN2 containing the ORF for the pre-
viously described and characterized scFv (AA2, TA10,
and SF9) [16,17] as well as the anti Rab1 scFv ROF7
Figure 6 Determination of a very precise region within myosin as the putative SF9 binding domain. Alignment of cDNA fragments
within the ORF (thick black line) of the three non-muscle myosin heavy chains. 196 cDNA fragments of MYH9 (A), 55 of MYH10 (B) and 61 of
MYH11 (C) were found in the screen, yielding SID of 35, 33 and 70 amino acids in length, respectively (depicted in red). B. Sequence alignment
of the three myosin-homologue SID (boxed) determines a precise 29-amino-acid long putative binding domain. Note almost complete (>93%)
amino acid sequence identity for the common SID (depicted in red).
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Figure 7 Confirmation of the binding of SF9 to an epitope within the common SID. A. Schematic alignment of the full-length human non-
muscle myosin IIA heavy chain (NMHCAIIA) protein, of the three found SID and of the constructs made to confirm SF9 binding. The common
(29aa long) SID is depicted in red. B. Analysis using immunofluorescence. HeLa cells were transfected with full-length NMHCAIIA (a-c) or the
NMHCIIA-∆C-ter fragment expressing only the first 1338 amino acids and lacking the common SID (d-f). Only the full length but not the
truncated recombinant GFP-tagged protein was recognized by hSF9 (yellow in panel c versus green in panel f). Bar 10 μm. C. Analysis using
immunoblot. HeLa cells were transfected with either a GFP-tagged NMHCIIA fragment containing the common SID (fragment, a), or a GFP-
tagged NMHCIIA fragment deleted from the common SID (∆SF9BD, b). Immunoblot analysis of total cell extracts showed that hSF9 only
detected the larger fragment (lane a) while the anti-GFP antibody recognized both recombinant proteins at ~70 kDa. D. Sequence alignment of
the 29-amino-acid long human non-muscle myosin IIA SID with the corresponding insect protein. Note the high level of similarity. E. Specific
binding of SF9 to the drosophila protein. Total cell extract of drosophila (S2) cells incubated (+) or not (-) with RNAi to inactivate the expression
of zipper (the unique myosin II homologue in drosophila) were analyzed by immunoblot. A specific band at ~200 kDa is present only in non
treated cells. Tubulin stained by an anti a-tubulin antibody was used as loading control.
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(unpublished data), were used for sub-cloning (via use of
the restriction enzymes NcoI and NotI) into a pBTM116
derived bait vector as described [38]. The generation of
random-primed human placenta and drosophila cDNA
libraries in SfiI polilynker adapted pGADGH plasmid
has been described previously as well [33,39]. In such
libraries, inserts have an average size of between 700
(drosophila) and 800 (human placenta) base pairs and
the complexity reaches over 50 million clones in E. coli.
The DNA of a maxiprep (Quiagen) prepared from E.
coli scraped colonies was transformed into yeast strain
Y187 using the classical lithium acetate protocol and
plated on four hundred 140 mm Petri plates. Conditions
were optimized by determining the linearity of colony
forming unit (cfu) as a function of DNA concentration
to avoid the transformation of individual yeast cells with
multiple plasmids, because this could lead to the identi-
fication of false positive clones. After colony formation,
the four hundred dishes were scraped. The resulting
cells were pooled, then aliquoted and stored in glycerol
40% at -80°C as equivalent fractions of the same library.
Screens were performed using a cell-to-cell mating
method described previously [40]. Briefly: four hundred
million prey cells were mixed with eight hundred mil-
lion bait cells and spread on YDP plates for four hour
to ensure mating but avoid replication of the already
formed diploid cells. This ensures a complete coverage
of the highly complex library because a minimum of
fifty million clones is tested (10 times the primary com-
plexity of the yeast transformed cDNA library). The
genetic saturation of the screens allows statistical analy-
sis of the results of each screen [33]. In addition, the
use of the same library for many screens permits the
identification of fragments that are highly connected
and thus are potential “false positives” [33]. Qualitative
comparison of lacZ reporter activation was done by
standard X-Gal Top agar overlay assay. For details of
the analysis of obtained clones see firsts paragraph
“Results and Discussion” section. Lists of specifically
interacting clones for each screen that are not provided
in this manuscript in Additional files 1 through 5 can be
requested from the corresponding author.
Cloning of expression plasmids for confirmation of
predicted epitopes
For expression of the scFv AA2 fused to the Green
fluorescent protein (GFP) in insect cells the mammalian
expression plasmid (pEGFP-N3NN-AA2, [17]) was
digested with EcoRI and XbaI. The released fragment
was then cloned into identical sites within the droso-
phila expression vector pMT/V5 (Invitrogen).
For TA10 related experiments an untagged full-length
giantin expression plasmid (pSG5-GCP364) was received
as a kind gift from Yoshio Misumi (Fukuoka, Japan).
The mammalian expression plasmid giantin ∆TABD
was generated by removing a 702-nucleotide long piece
by cutting (and subsequently religating) with PmlI
within the ORF of giantin of the plasmid pSG5-GCP364.
For the generation of the plasmid giantin-TA10BDshort
the following primers were used for PCR: Forward 5’-
CCC AAG CTT TGT GAG CTA AAG AAG CAG CC
-3’ and Reverse 5’- CGG GAT CCT TAC TTT CCT
AGG AGT GCA TC -3’. For giantin-79aa control the
following primers were used for PCR: Forward 5’- CCC
AAG CTT AGC CAG GTT TCT GTT CAG AAT -3’
and Reverse 5’- CGG GAT CCT TAT TCG GTG CTC
TCT GCA ATC TT -3’. For both PCR reactions pSG5-
GCP364 was used as the template. Amplified segments
were digested with HindIII and BamHI (visualized in
Italics in the primers) and inserted into a pEGFP
expression vector prepared by digestion with the same
enzymes.
For experiments regarding scFv SF9 we obtained the
expression plasmid containing the full-length non-mus-
cle myosin heavy chain IIA (pTRE GFP NMHCIIA)
from Robert Adelstein (National Institutes of Health
Bethesda, MD, U.S.A.) via Addgene®. NMHCIIA-∆C-ter
was generated by digesting pTRE GFP NMHCIIA with
EcoRI and SpeI, blunting with Klenow and religating,
thus creating a truncated fusion protein lacking the last
620 aa of MNHCIIA. In order to remove only the 29
amino acid long putative SF9 binding domain in its C-
terminal portion the following multi-step strategy was
used: (i) PCR amplification of a NMHCIIA fragment
ranging from the end of the putative SF9 binding
domain until beyond the unique SacII site creating a
KpnI site at the 5’-end using the following primers: For-
ward1 5’-GGG GTA CCA TGA AGG CCC AGT TCG
AGC GG-3’ (KpnI site in Italics), Reverse1 5’-AGG
TCG GTG TTG ATC TGG TC-3’; (ii) insertion of the
digested PCR product (PCR I) into the pEGFP-C1 vector
(Clontech) equally digested with KpnI and SacII; (iii) a
second PCR amplification (PCR II) using the same
NMHCIIA-template, a forward primer before the unique
EcoRI site (Forward2 5’-AAA GGG GAC TCG GAG
CAC-3’) and a reverse primer annealing just before the
beginning of the putative SF9 binding domain again
containing a KpnI site in frame (Reverse2 5’-GGG GTA
CCC TCC ACC TGC TGC TCT AGG GC-3’, KpnI site
in Italics); (iv) digestion of both, the PCR II product as
well as the pEGFP-C1 vector containing PCR I with
KpnI and EcoRI and insertion of the former into the lat-
ter creating the plasmid pEGFP-fragment-∆SF9BD (non
muscle myosin heavy chain II A fragment delta SF9
binding domain). In a separate reaction the original
pTRE-GFP-NMHCIIA as well as the empty plasmid
pEGFP-C1 were digested with EcoRI and SacII and the
1055 bp MYH9 fragment was inserted in frame with
Vielemeyer et al. BMC Biotechnology 2010, 10:59
http://www.biomedcentral.com/1472-6750/10/59
Page 10 of 13
GFP creating the plasmid pEGFP-fragment. All con-
structs were verified by sequencing.
Cell cultures, immunofluorescence and immunoblotting
analyses
HeLa cells were grown under standard conditions and
transfected as described [16]. For immunofluorescence
respective scFv (AA2, TA10, SF9) were first converted to
dimeric mini-antibodies (hAA2, hTA10, hSF9) by adding
a human Fc portion as described before [41]. For immu-
nofluorescence experiments cells were then incubated
with secondary anti-human antibodies (Jackson Immu-
noResearch Laboratories, Westgrove, PA, USA and
Molecular Probes, Eugene, OR, USA). For immunoblot-
ting, total cell lysates of transfected HeLa cells were
boiled in sample buffer and subjected to SDS-PAGE.
After transfer onto nitrocellulose, membranes were
blocked and then incubated with mouse anti-GFP antibo-
dies (Roche Diagnostics GmbH, Mannheim Germany),
with the humanized scFv hSF9 or with mouse anti a-
tubulin antibodies (B-5-1-2, Sigma Aldrich) and revealed
with ECL after incubation with respective secondary anti-
bodies coupled with horseradish peroxidase. Transfection
of the fragment constructs with a predicted molecular
weight of ~70 kDa (see details in Figure 4C) were used
for immunoblotting, since non-muscle myosin is present
abundantly in HeLa cells and it is difficult to visualize the
overexpressed protein as an additional band given the
size of non-muscle myosin heavy chain (~200kDa).
Drosophila S2 and S2R cells were grown and prepared
for transfection and immunofluorescence as described
elsewhere [42]. Briefly, S2 cells were plated into 24-well
plates (BD Falcon) at 160,000 cells/well in 1 mL growth
medium (Schneider’s Drosophila medium (GIBCO, sup-
plemented with 10% heat inactivated fetal calf serum).
Cells were subsequently transfected with plasmid DNA
using the CaPO4 method [43]. The following day, trans-
fected cells were plated on glass cover slips coated with
concavalin A and after 20 minutes fixed for 5 min with
4% paraformaldehyde in PBS or with 100% methanol at
-20°C. Incubation with primary and secondary antibo-
dies of transfected or non-transfected S2 and S2R cells
was performed as described above for HeLa cells.
For knock down of zipper (myosin II homologue in
drosophila) dsRNAs were prepared as described using
the following primers: left primer: 5’-CCT AAA GCC
ACT GAC AAG ACG-3’ right primer: 5’-CGG TAC
AAG TTC GAG TCA AGC-3’ creating a PCR product
of 647 bp. T7 sites were added symmetrically and pro-
cessed as before [42].
Gap Repair for TA10 Epitope determination
Seventeen PCR fragments of different size were gener-
ated using as matrix the A-135 prey clone (Additional
file 4). At the extremity of each fragment, 50 nucleotides
corresponding to the polylinker of the prey vector were
added to allow “gap repair” recombination. The trans-
formation of the two-hybrid yeast strain containing
TA10 bait plasmid with the PCR product and a digested
prey plasmid resulted in the production of yeast trans-
formants containing the bait and different prey frag-
ments. The interactions of the prey fragment were
tested by spotting in minus histidine media and by b-
galactosidase qualitative observation. All fragments were
aligned along the ORF of giantin.
Additional material
Additional file 1: AA2 Two Hybrid Screen Results using human
cDNA library. A table listing the identity of all the hits recovered in the
two-Hybrid screen using AA2 as a bait against a human cDNA library.
The table presents the name and accession number of each prey
(identified by alignment, see materials and methods), the nucleotide start
and stop of the insert, whether it is in frame or out of frame (OOF), its
sense in the prey vector and the calculated PBS score (see materials and
methods).
Additional file 2: AA2 Two Hybrid Screen Results using drosophila
cDNA library. A table listing the identity of all the hits recovered in the
two-Hybrid screen using AA2 as a bait against a drsophila cDNA library.
The table presents the name and accession number of each prey
(identified by alignment, see materials and methods), the nucleotide start
and stop of the insert, whether it is in frame or out of frame (OOF), its
sense in the prey vector and the calculated PBS score (see materials and
methods).
Additional file 3: ROF7 Two Hybrid Screen Results using human
cDNA library. A table listing the identity of all the hits recovered in the
two-Hybrid screen using ROF7 as a bait against a human cDNA library.
The table presents the name and accession number of each prey
(identified by alignment, see materials and methods), the nucleotide start
and stop of the insert, whether it is in frame or out of frame (OOF), its
sense in the prey vector and the calculated PBS score (see materials and
methods).
Additional file 4: TA10 Two Hybrid Screen Results using human
cDNA library. A table listing the identity of all the hits recovered in the
two-Hybrid screen using TA10 as a bait against a human cDNA library.
The table presents the name and accession number of each prey
(identified by alignment, see materials and methods), the nucleotide start
and stop of the insert, whether it is in frame or out of frame (OOF), its
sense in the prey vector and the calculated PBS score (see materials and
methods).
Additional file 5: SF9 Two Hybrid Screen Results using human
cDNA library. A table listing the identity of all the hits recovered in the
two-Hybrid screen using SF9 as a bait against a human cDNA library. The
table presents the name and accession number of each prey (identified
by alignment, see materials and methods), the nucleotide start and stop
of the insert, whether it is in frame or out of frame (OOF), its sense in
the prey vector and the calculated PBS score (see materials and
methods).
Acknowledgements
The authors greatly acknowledge the Nikon Imaging Centre @ Institut Curie-
CNRS and the PICT-IBiSA Imaging Facility of the Curie Institute, Paris for
technical support, and Sandrine Moutel for her invaluable help and advice.
The project was supported by the French Agence Nationale de la Recherche
(“ANR”) BiotecS-ANR-09-BIOT-005 (FP and JCR). The work was also supported
by the ANR program Blanc, ANR-06-BLANC-0107 (BG and FP), by the Human
Vielemeyer et al. BMC Biotechnology 2010, 10:59
http://www.biomedcentral.com/1472-6750/10/59
Page 11 of 13
Science Frontier Organization (FP), by the Curie Institute, Paris, France, and
by the Centre National de la Recherche Scientifique (CNRS) of France.
The full-length giantin expression plasmid (pSG5-GCP364) was received as a
kind gift from Yoshio Misumi (Fukuoka, Japan).
Author details
1Institut Curie - Research Center, 26 rue d’Ulm, 75248 Paris cedex 05, France.
2CNRS, UMR144, 26 rue d’Ulm, 75248 Paris, cedex 05, France. 3U830 INSERM,
26, rue d’Ulm, 75248 Paris cedex 05, France. 4Hybrigenics Inc., 3-5 impasse
Reille, 75014 Paris, France. 5Drexel University School of Medicine, Division of
Infectious Diseases &HIV Medicine, 245N 15th Street, NCB 6th floor,
Philadelphia, PA 19102, USA. 6Université Joseph Fourier (Grenoble)
Laboratoire de Spectrométrie Physique, CNRS, BP87 (UMR5588) 140 Av. de la
physique, 38402 Saint Martin d’Hères, France. 7Institut Pasteur, Membrane
Traffic and Cell Division Lab, CNRS URA2582,26 rue du Dr. Roux, 75015 Paris,
France.
Authors’ contributions
CN initiated the project, constructed the first plasmids and contributed to
the writing of the manuscript. OV wrote the manuscript and carried out
most of the characterization experiments with the help of AJJ. AE was
involved in experiments using drosophila cells. BG supported the work and
participated in its critical analysis. JCR carried out all yeast two hybrid
experiments including molecular biology related to it. FP, JC and JCR
designed the study. FP and JCR were involved in writing the manuscript,
supported and directed the work. All authors read and approved the final
manuscript.
Received: 26 April 2010 Accepted: 22 August 2010
Published: 22 August 2010
References
1. Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat
Biotechnol 2005, 23(9):1147-1157.
2. Deonarain MP: Recombinant antibodies for cancer therapy. Expert Opin
Biol Ther 2008, 8(8):1123-1141.
3. Maggon K: Monoclonal antibody “gold rush”. Curr Med Chem 2007,
14(18):1978-1987.
4. Nelson AL, Reichert JM: Development trends for therapeutic antibody
fragments. Nat Biotechnol 2009, 27(4):331-337.
5. O’Brien S, Albitar M, Giles FJ: Monoclonal antibodies in the treatment of
leukemia. Curr Mol Med 2005, 5(7):663-675.
6. Presta LG: Selection, design, and engineering of therapeutic antibodies. J
Allergy Clin Immunol 2005, 116(4):731-736, quiz 737.
7. Reichert JM, Valge-Archer VE: Development trends for monoclonal
antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6(5):349-356.
8. Schaedel O, Reiter Y: Antibodies and their fragments as anti-cancer
agents. Curr Pharm Des 2006, 12(3):363-378.
9. Weiner GJ: Monoclonal antibody mechanisms of action in cancer.
Immunol Res 2007, 39(1-3):271-278.
10. Filpula D: Antibody engineering and modification technologies. Biomol
Eng 2007, 24(2):201-215.
11. Smith GP: Filamentous fusion phage: novel expression vectors that
display cloned antigens on the virion surface. Science 1985,
228(4705):1315-1317.
12. Hoogenboom HR: Overview of antibody phage-display technology and
its applications. Methods Mol Biol 2002, 178:1-37.
13. Kretzschmar T, von Ruden T: Antibody discovery: phage display. Curr Opin
Biotechnol 2002, 13(6):598-602.
14. Weisser NE, Hall JC: Applications of single-chain variable fragment
antibodies in therapeutics and diagnostics. Biotechnol Adv 2009,
27(4):502-520.
15. Dimitrov A, Quesnoit M, Moutel S, Cantaloube I, Pous C, Perez F: Detection
of GTP-tubulin conformation in vivo reveals a role for GTP remnants in
microtubule rescues. Science 2008, 322(5906):1353-1356.
16. Nizak C, Martin-Lluesma S, Moutel S, Roux A, Kreis TE, Goud B, Perez F:
Recombinant antibodies against subcellular fractions used to track
endogenous Golgi protein dynamics in vivo. Traffic 2003, 4(11):739-753.
17. Nizak C, Monier S, del Nery E, Moutel S, Goud B, Perez F: Recombinant
antibodies to the small GTPase Rab6 as conformation sensors. Science
2003, 300(5621):984-987.
18. Nizak C, Sougrat R, Jollivet F, Rambourg A, Goud B, Perez F: Golgi
inheritance under a block of anterograde and retrograde traffic. Traffic
2004, 5(4):284-299.
19. Frillingos S, Sahin-Toth M, Wu J, Kaback HR: Cys-scanning mutagenesis: a
novel approach to structure function relationships in polytopic
membrane proteins. Faseb J 1998, 12(13):1281-1299.
20. Rimon A, Hunte C, Michel H, Padan E: Epitope Mapping of
Conformational Monoclonal Antibodies Specific to NhaA Na(+)/H(+)
Antiporter: Structural and Functional Implications. J Mol Biol 2008,
379(3):471-481.
21. Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, Freund NT, Bublil EM,
Ruppin E, Sharan R, Gershoni JM, et al: Pepitope: epitope mapping from
affinity-selected peptides. Bioinformatics 2007, 23(23):3244-3246.
22. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R,
Pupko T: Epitope mapping using combinatorial phage-display libraries: a
graph-based algorithm. Nucleic Acids Res 2007, 35(1):69-78.
23. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A,
Rubinstein ND, Pupko T, Gershoni JM: Stepwise prediction of
conformational discontinuous B-cell epitopes using the Mapitope
algorithm. Proteins 2007, 68(1):294-304.
24. Rinaudo CD, Telford JL, Rappuoli R, Seib KL: Vaccinology in the genome
era. J Clin Invest 2009, 119(9):2515-2525.
25. Sette A, Peters B: Immune epitope mapping in the post-genomic era:
lessons for vaccine development. Curr Opin Immunol 2007, 19(1):106-110.
26. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A: Selection of
antibodies for intracellular function using a two-hybrid in vivo system.
Proc Natl Acad Sci USA 1999, 96(21):11723-11728.
27. Biocca S, Neuberger MS, Cattaneo A: Expression and targeting of
intracellular antibodies in mammalian cells. Embo J 1990, 9(1):101-108.
28. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A: The
intracellular antibody capture technology (IACT): towards a consensus
sequence for intracellular antibodies. J Mol Biol 2002, 317(1):73-83.
29. Visintin M, Meli GA, Cannistraci I, Cattaneo A: Intracellular antibodies for
proteomics. J Immunol Methods 2004, 290(1-2):135-153.
30. Visintin M, Quondam M, Cattaneo A: The intracellular antibody capture
technology: towards the high-throughput selection of functional
intracellular antibodies for target validation. Methods 2004, 34(2):200-214.
31. Feldhaus MJ, Siegel RW: Yeast display of antibody fragments: a discovery
and characterization platform. J Immunol Methods 2004, 290(1-2):69-80.
32. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W,
Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein
database search programs. Nucleic Acids Res 1997, 25(17):3389-3402.
33. Formstecher E, Aresta S, Collura V, Hamburger A, Meil A, Trehin A,
Reverdy C, Betin V, Maire S, Brun C, et al: Protein interaction mapping: a
Drosophila case study. Genome Res 2005, 15(3):376-384.
34. Garcia-Saez I, Tcherniuk S, Kozielski F: The structure of human neuronal
Rab6b in the active and inactive form. Acta Crystallogr D Biol Crystallogr
2006, 62(Pt 7):725-733.
35. der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C,
Escher D, Pluckthun A, Barberis A: Direct in vivo screening of intrabody
libraries constructed on a highly stable single-chain framework. J Biol
Chem 2002, 277(47):45075-45085.
36. Philibert P, Stoessel A, Wang W, Sibler AP, Bec N, Larroque C, Saven JG,
Courtete J, Weiss E, Martineau P: A focused antibody library for selecting
scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 2007,
7:81.
37. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A,
Backmann N, Conrath K, Muyldermans S, Cardoso MC, et al: Targeting and
tracing antigens in live cells with fluorescent nanobodies. Nat Methods
2006, 3(11):887-889.
38. Vojtek AB, Hollenberg SM: Ras-Raf interaction: two-hybrid analysis.
Methods Enzymol 1995, 255:331-342.
39. Colland F, Daviet L: Integrating a functional proteomic approach into the
target discovery process. Biochimie 2004, 86(9-10):625-632.
40. Fromont-Racine M, Rain JC, Legrain P: Building protein-protein networks
by two-hybrid mating strategy. Methods Enzymol 2002, 350:513-524.
Vielemeyer et al. BMC Biotechnology 2010, 10:59
http://www.biomedcentral.com/1472-6750/10/59
Page 12 of 13
41. Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dubel S, Perez F:
A multi-Fc-species system for recombinant antibody production. BMC
Biotechnol 2009, 9:14.
42. Echard A, Hickson GR, Foley E, O’Farrell PH: Terminal cytokinesis events
uncovered after an RNAi screen. Curr Biol 2004, 14(18):1685-1693.
43. Jordan M, Schallhorn A, Wurm FM: Transfecting mammalian cells:
optimization of critical parameters affecting calcium-phosphate
precipitate formation. Nucleic Acids Res 1996, 24(4):596-601.
doi:10.1186/1472-6750-10-59
Cite this article as: Vielemeyer et al.: Characterization of single chain
antibody targets through yeast two hybrid. BMC Biotechnology 2010
10:59.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vielemeyer et al. BMC Biotechnology 2010, 10:59
http://www.biomedcentral.com/1472-6750/10/59
Page 13 of 13
